Passage BIO, Inc. (PASG)

A. Company Overview

Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines to address neurodegenerative diseases. Founded in 2017 and incorporated in Delaware, the company is headquartered in Philadelphia, Pennsylvania. The primary objective of Passage Bio is to create innovative, one-time gene therapies that target the underlying causes of such conditions, leveraging advanced research and collaborations with leading academic institutions.

B. Business Model and Strategic Focus

Passage Bio operates with a unique business model that emphasizes a gene therapy approach to neurodegenerative diseases, specifically those affecting the central nervous system (CNS). The company is particularly focused on conditions for which existing treatment options are limited, and seeks to improve clinical outcomes through the restoration of gene functionality. By targeting the pathophysiology of diseases at the genetic level, Passage Bio aims to provide effective therapeutic alternatives, working towards the goal of enhancing the quality of life for patients afflicted with these conditions.

To support this mission, Passage Bio has established strategic collaborations, notably with the University of Pennsylvania's Gene Therapy Program, led by a key figure in the field, Dr. James Wilson. This collaboration provides access to advanced research capabilities, including preclinical development and access to innovative gene delivery technology.

C. Lead Product Candidate: PBFT02

The lead product candidate from Passage Bio is PBFT02, a gene therapy designed to treat frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). The therapy utilizes an adeno-associated virus (AAV1) capsid to deliver a functional copy of the GRN gene directly to the CNS through intra cisterna magna (ICM) administration. PBFT02 aims to elevate progranulin levels, thus restoring lysosomal function and potentially slowing disease progression.

Preclinical studies suggest that increased levels of progranulin may have beneficial effects across various neurodegenerative disorders, including FTD-C9orf72, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease (AD), particularly in patients with genetic predispositions due to polymorphisms affecting progranulin levels. The company anticipates regulatory feedback regarding the treatment pathway for additional neurodegenerative diseases in the near future.

D. Clinical Trials and Pipeline Development

Passage Bio's clinical pipeline consists primarily of development programs for PBFT02. The company has initiated the upliFT-D trial, which is an international, open-label Phase 1/2 study to evaluate the safety and efficacy of PBFT02 in patients diagnosed with symptomatic FTD-GRN. Initial data from this trial have indicated a promising safety profile with elevated levels of progranulin detected in cerebrospinal fluid post-treatment.

In addition to PBFT02, Passage Bio has several other product candidates aimed at addressing pediatric indications, including GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD), which are currently in various stages of development. However, clinical development for some of these candidates has been paused as the company evaluates out-licensing opportunities.

E. Collaborations and Research Initiatives

The collaboration with the University of Pennsylvania is pivotal to Passage Bio’s research and development strategy. This partnership facilitates access to cutting-edge technologies and expertise in gene therapy and enables extensive preclinical validation of potential therapeutic candidates. The agreement allows Passage Bio to explore multiple CNS indications, both rare and non-rare, with the expectation of advancing promising candidates through rigorous testing protocols.

F. Manufacturing and Regulatory Strategy

Passage Bio has developed robust internal capabilities for the chemistry, manufacturing, and control (CMC) processes necessary for producing AAV-based therapeutics. The company employs a well-defined manufacturing approach that includes partnerships with external firms for large-scale production of clinical supplies. The company’s focus on optimizing manufacturing processes is integral to ensuring quality, reliability, and regulatory compliance in the production of its gene therapies.

The regulatory strategy includes securing necessary approvals from the U.S. Food and Drug Administration (FDA) and other international agencies, and taking advantage of designations such as Orphan Drug Designation and Fast Track Designation to expedite the development of therapies targeted at rare diseases.

G. Competitive Landscape

In the biotechnology sector, particularly within the gene therapy field, Passage Bio faces competition from a variety of entities, including larger pharmaceutical companies, specialized biotech firms, and academic institutions. Key competitors also developing therapeutic options for FTD-GRN include Alector, Inc., Prevail Therapeutics (now part of Eli Lilly), and various other companies exploring advanced genetic approaches. The firm’s competitive edge lies in its focused strategic partnerships, innovative therapeutic candidates, and a strong foundational understanding of genetic medicine.